More About the Risk of Ibrutinib-associated Bleeding.
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico, Modena, Italy.
Ambra
A
Paolini
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico, Modena, Italy.
Valeria
V
Coluccio
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico, Modena, Italy.
Mario
M
Luppi
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Hematology Unit, AOU Policlinico, Modena, Italy.
Marco
M
Marietta
D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D012720:Severity of Illness Index
D000970:Antineoplastic Agents; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000225:Adenine